REVB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
3.4M
-7.6%
3.7M
+18.4%
3.1M
+20.3%
2.6M
+32.4%
1.9M
R&D
1.5M
-21.1%
1.9M
+39.3%
1.4M
+42.8%
964.2K
+4.5%
922.9K
SG&A
1.9M
+7.3%
1.7M
+1.6%
1.7M
+6.7%
1.6M
+57.6%
1.0M
Operating Income
-3383576
+7.6%
-3662241
-18.4%
-3092500
-20.3%
-2571588
-32.4%
-1943011
EBITDA
-3375391
+7.6%
-3653928
-18.4%
-3085297
-20.2%
-2565736
-32.5%
-1936246
Net Income
-3315513
+0.2%
-3323384
-10.4%
-3009051
-19.8%
-2511006
-31.7%
-1907176
EPS (Basic)
$-5.92
+2.8%
$-6.09
+67.9%
$-18.97
-66.3%
$-11.41
+77.0%
$-49.51
EPS (Diluted)
$-5.92
+2.8%
$-6.09
+67.9%
$-18.97
-66.3%
$-11.41
+77.0%
$-49.51
Shares (Diluted)
559.6K
+2.3%
547.1K
+19.4%
458.2K
+108.2%
220.0K
+133.0%
94.5K
Revelation Biosciences (REVB) — Financials